



EMLc

ATC codes: J02AA01

Indication	Aspergillosis <span style="background-color: #00a651; color: white; padding: 2px;">ICD11 code: 1F20.Z</span>
INN	Amphotericin B
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	*Liposomal amphotericin B has a better safety profile than the sodium deoxycholate formulation and should be prioritized for selection and use depending on local availability and cost.
Formulations	Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex) ; 50 mg in vial powder for injection (as sodium deoxycholate)
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1984 ( <a href="#">TRS 722</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Changed in 2013 ( <a href="#">TRS 985</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Amphotericin B</a> 
DrugBank	<a href="#">Amphotericin b</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.

